New drug combo aims to outperform standard therapy in HER2+ breast cancer
NCT ID NCT04425018
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This phase 2 trial tests whether a newer drug, margetuximab, combined with chemotherapy, works better than the standard trastuzumab combination for HER2-positive breast cancer before surgery. The study includes 174 people with stage II or III disease who have a specific genetic variant. The main goal is to see which combination leads to no cancer remaining at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine Medical Center
Houston, Texas, 77030, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dana-Farber Brigham Cancer Center - Foxborough
Foxborough, Massachusetts, 02035, United States
-
Dana-Farber at Milford
Milford, Massachusetts, 01757, United States
-
Dana-Farber at South Shore Hospital
Weymouth, Massachusetts, 02190, United States
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
MedStar Washington Hospital Center
Washington D.C., District of Columbia, 20010, United States
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
-
UPMC Hillman Cancer Center - Arnold Palmer at Mountain View
Greensburg, Pennsylvania, 15601, United States
-
UPMC Hillman Cancer Center - Arnold Palmer at Norwin
Irwin, Pennsylvania, 15642, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
University of Washington Fred Hutchinson Cancer Care
Seattle, Washington, 98109, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Margetuximab (Margenza) and Trastuzumab (Herceptin), both given with chemotherapy (Paclitaxel and Pertuzumab)
What this could lead to
If margetuximab proves more effective, it could offer a new pre-surgery treatment option for HER2-positive breast cancer patients with a specific genetic profile.
What could go wrong
This is a mid-stage trial with only 174 participants, so results may not apply to everyone. The new drug may not work better than the current standard, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.